Key Record Dates
| ClinicalTrials.gov Identifier: | NCT05687266 |
|---|---|
| Brief Title: | Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations (AVANZAR) |
| First Submitted : | December 28, 2022 |
| First Submitted that Met QC Criteria : | January 17, 2023 |
| First Posted : | January 18, 2023 |
| Last Update Submitted that Met QC Criteria : | April 8, 2024 |
| Last Update Posted : | April 9, 2024 |